Heart-Smart cancer care: team approach tested in breast cancer patients
NCT ID NCT01621659
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether extra care from a team of heart doctors, dietitians, exercise therapists, pharmacists, and physiotherapists can reduce side effects in breast cancer patients receiving chemotherapy. About 80 participants will be randomly assigned to either the team intervention or usual care. The main goal is to see if this approach helps preserve heart function during and after cancer treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
multidisciplinary team intervention (cardiology, nutrition, exercise, pharmacy, physiotherapy assessments and counseling)
What this could lead to
If it works, this could show that extra support from multiple health experts reduces heart damage and improves quality of life during and after cancer treatment.
What could go wrong
This is a small, early-phase study with only 80 participants, so results may not apply to everyone. The extra care may not significantly improve outcomes over usual care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2, Canada